In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 227-237

  Mueller, C ^a   Strayer, M S ^b   Sirninger, J ^c   Braag, S ^a   Branco, F ^b   Louboutin, J P ^b   Flotte, T R ^a   Strayer, D S ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

CFTR; Cystic fibrosis; Gutless; Pseudomonas; SV40

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1BETA; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYSTIC FIBROSIS; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIMIAN VIRUS 40; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WEIGHT REDUCTION;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINES; DNA, COMPLEMENTARY; FEASIBILITY STUDIES; GENE THERAPY; GENETIC VECTORS; LUNG; MICE; MICE, KNOCKOUT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SIMIAN VIRUS 40; TRANSDUCTION, GENETIC;

MIRIDAE; MUS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 76749131499     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.137     Document Type: Article

References (37)

1. Schwiebert EM, Benos DJ, Fuller CM. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein. Am J Med 1998; 104: 576-590.
2. Southern KW. delta F508 in cystic fibrosis: willing but not able. Arch Dis Child 1997; 76: 278-282.
3. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2004; 11: 805-810.
4. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002; 54: 1373-1393.
5. Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Annu Rev Physiol 2003; 65: 585-612.
6. Griesenbach U, Ferrari S, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Therapy 2002; 9: 1344-1350.
7. Flotte TR. Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy. Curr Opin Mol Ther 2001; 3: 497-502.
8. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 2008; 35: 164-178.
9. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104: 1245-1255.
10. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR. Inhibition of recombinant adeno-associated virus (rAAV) trans-duction by bronchial secretions from cystic fibrosis patients. Gene Therapy 2000; 7: 1783-1789.
11. Zeitlin PL. Cystic fibrosis gene therapy trials and tribulations. Mol Ther 2000; 1: 5-6.
12. Strayer D, Branco F, Zern MA, Yam P, Calarota SA, Nichols CN et al. Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol Ther 2002; 6: 227-237.
13. Strayer DS, Zern MA, Chowdhury JR. What can SV40-derived vectors do for gene therapy? Curr Opin Mol Ther 2002; 4: 313-323.
14. Norkin LC. Simian virus 40 infection via MHC class I molecules and caveolae. Immunol Rev 1999; 168: 13-22.
15. Pelkmans L, Puntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 2002; 296: 535-539.
16. Kondo R, Feitelson MA, Strayer DS. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Therapy 1998; 5: 575-582.
17. Strayer DS, Lamothe M, Wei D, Milano J, Kondo R. Generation of recombinant SV40 vectors for gene transfer. Methods Mol Biol 2001; 165: 103-117.
18. Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA 1990; 87: 4012-4016.
19. Egan ME, Glockner-Pagel J, Ambrose C, Cahill PA, Pappoe L, Balamuth N et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-492.
20. West MR, Molloy CR. A microplate assay measuring chloride ion channel activity. Anal Biochem 1996; 241: 51-58.
21. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100: 2810-2815.
22. Sirninger J, Muller C, Braag S, Tang Q, Yue H, Detrisac C et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004; 15: 832-841.
23. Dajani R, Zhang Y, Taft PJ, Travis SM, Starner TD, Olsen A et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am J Respir Cell Mol Biol 2005; 32: 548-552.
24. Akinbi HT, Epaud R, Bhatt H, Weaver TE. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol 2000; 165: 5760-5766.
25. Wiley SR, Kraus RJ, Zuo F, Murray EE, Loritz K, Mertz JE. SV40 early-to-late switch involves titration of cellular transcriptional repressors. Genes Dev 1993; 7: 2206-2219.
26. Pasyk EA, Foskett JK. Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl-channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 1995; 270: 12347-12350.
27. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-25.
28. Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Therapy 1996; 3: 797-801.
29. Flotte TR. Recombinant adeno-associated virus gene therapy for cystic fibrosis and alpha(1)-antitrypsin deficiency. Chest 2002; 121(3 Suppl): 98S-102S.
30. Mueller C, Flotte TR. Clinical gene therapy using recom-binant adeno-associated virus vectors. Gene Therapy 2008; 15: 858-863.
31. Sauter BV, Parashar B, Chowdhury NR, Kadakol A, Ilan Y, Singh H et al. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology 2000; 119: 1348-1357.
32. Middleton PG, Alton EW. Gene therapy for cystic fibrosis: which postman, which box? [see comments]. Thorax 1998; 53: 197-199.
33. Ferkol T, Perales JC, Eckman E, Kaetzel CS, Hanson RW, Davis PB. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. J Clin Invest 1995; 95: 493-502.
34. Strayer DS, Milano J. SV40 mediates stable gene transfer in vivo. Gene Therapy 1996; 3: 581-587.
35. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12: 751-761.
36. Zahm JM, Debordeaux C, Maurer C, Hubert D, Dusser D, Bonnet N et al. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions. Am J Respir Crit Care Med 2001; 163: 1153-1157.
37. Louboutin JP, Liu B, Chekmasova AA, Reyes BA, van Bockstaele EJ, Strayer DS. Delivering genes to the organ-localized immune system: long-term results of direct intramarrow transduction. J Gene Med 2007; 9: 843-851.